Sarepta settles patent litigation with REGENXBIO, UPenn, Catalent over gene therapy capsid
Sarepta will pay REGENXBIO $39.0 million to resolve patent infringement suits tied to the AAVrh74 capsid used in ELEVIDYS.
SEC filing
Latest
3 stories
Wednesday, September 23
REGENXBIO, UPenn settle patent suit with Sarepta over ELEVIDYS
Sarepta will pay REGENXBIO $39.0 million and both sides drop patent litigation tied to ELEVIDYS manufacturing.
SEC filing
Wednesday, August 5
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates
New chief executive takes over as company narrows 2026 revenue guidance and reports progress in DM1, FSHD and Huntington's disease programs.
SEC filing